BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

OncoMed Pharmaceuticals, Inc. 

800 Chesapeake Drive

Redwood City  California  94063  U.S.A.
Phone: 650-995-8200 Fax: 650-298-8600


SEARCH JOBS




Industry
Pharmaceutical

Segment
Start Up





 Company News
OncoMed Pharmaceuticals, Inc. (OMED) Begins Patient Dosing In Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer 12/1/2014 9:46:30 AM
OncoMed Pharmaceuticals, Inc. (OMED) Presents New Clinical And Biomarker Data From Its Tarextumab And Demcizumab Clinical Trials At The European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium 11/24/2014 12:55:50 PM
OncoMed Pharmaceuticals, Inc. (OMED) To Present At Piper Jaffray Healthcare Conference 11/21/2014 10:01:04 AM
OncoMed Pharmaceuticals, Inc. (OMED) Presents Biomarker-Focused Clinical Data From Phase 1a Trial Of Anti-Notch1 (OMP-52M51) In Oral Plenary Session At The 26th OncoMed Pharmaceuticals, Inc. (OMED)-European Organization for Research and Treatment of Cancer-National Cancer Institute Symposium 11/19/2014 9:35:09 AM
OncoMed Pharmaceuticals, Inc. (OMED) Announces Third Quarter 2014 Financial And Operating Results 11/5/2014 7:44:50 AM
OncoMed Pharmaceuticals, Inc. (OMED) Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent In The U.S. 11/3/2014 7:50:40 AM
OncoMed Pharmaceuticals, Inc. (OMED) To Present Clinical And Preclinical Data At The 26th European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium On Molecular Targets And Cancer Therapeutics Meeting 10/30/2014 10:54:41 AM
OncoMed Pharmaceuticals, Inc. (OMED) To Announce Financial Results For The Third Quarter 2014 On Tuesday, November 4, 2014, After Close Of U.S.-Based Financial Markets 10/29/2014 7:55:03 AM
OncoMed Pharmaceuticals, Inc. (OMED) To Present At The 13th Annual Biotechnology Industry Organization (BIO) Investor Forum 10/7/2014 7:53:52 AM
OncoMed Pharmaceuticals, Inc. (OMED) Announces Selection Of First Small Molecule Product Candidate Targeting The Wnt Pathway Under Collaboration With Bayer Pharma AG 9/30/2014 7:57:24 AM
12345678910...